^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IO112

    i
    Other names: IO112, arginase-1 peptide vaccine, IO 112, IO-112, ARGLong2, ARG1-18,19,20
    Associations

    News

    Trials
    Company:
    IO Biotech
    Drug class:
    ARG1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost3years
    Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=13, Completed, Herlev Hospital | Unknown status --> Completed | N=10 --> 13
    Trial completion • Enrollment change • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    IO112
    over3years
    Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial. (PubMed, Front Immunol)
    The patients received an arginase-1 peptide vaccine comprising three 20-mer peptides from the ARG1 immunological "hot spot" region in combination with the adjuvant Montanide ISA-51...Nine (90%) of ten patients had measurable peptide-specific responses in the periphery blood, and two (20%) of ten patients attained stable disease on protocol treatment. https://clinicaltrials.gov/ct2/show/NCT03689192, identifier NCT03689192.
    P1 data • Clinical Trial,Phase I • Journal
    |
    CD4 (CD4 Molecule)
    |
    IO112
    almost4years
    Modulating tumor microenvironment with arginase-1 specific T cells (CIMT 2022)
    Our study provides evidence that IO112 immune therapy against arginase-1 is an attractive way of modulating the immune suppressive tumor microenvironment for therapeutic benefit. With this rationale, we are currently undertaking IND enabling studies to explore this approach in a clinical setting.
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL13 (Interleukin 13) • IL4 (Interleukin 4)
    |
    IO112
    6years
    Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=10, Recruiting, Herlev Hospital | Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
    Clinical • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    IO112